Roche agrees to pay $2.4 billion to buy the rest of Foundation Medicine

Roche agrees to pay $2.4 billion to buy the rest of Foundation Medicine

Swiss drugmaker Roche Holding AG has agreed to pay $137 per share to buy the rest of Foundation Medicine (FMI), a $2.4 billion transaction that values the U.S. genomic profiling group at $5.3 billion, the partners said on Tuesday. The deal, backed by the boards of both companies, is set to close in the second half of this year, they said in a statement. The offer price represented a premium of 29 percent to FMI’s…

Read More